Drug intelligence / Profile preview

Lactobacillus salivarius BL 3123

Development stage: Unknown
Lead developer: Centre Hospitalier Universitaire de Clermont-Ferrand
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus salivarius BL 3123 is a specific probiotic bacterial strain that has been evaluated by the University Hospital, Clermont-Ferrand for its survival and behavior within the human gastrointestinal tract. As a live biotherapeutic product, the strain's efficacy is dependent on its ability to remain viable through gastric transit and reach the small and large intestines. Clinical research has specifically compared different delivery formats, including powder, standard tablets, and innovative retarded-release formulations, to optimize intestinal delivery in both healthy individuals and patients with an ileostomy. The strain is part of the broader category of microbiome-modulating therapies aimed at improving digestive health and restoring microbial balance.

Other names: Lactobacillus salivarius BL 3123-University Hospital, Clermont-Ferrand

Beyond the preview

Go deeper on Lactobacillus salivarius BL 3123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus salivarius BL 3123.

Explore the full profile